Catalyst Wire Dossier Catalyst Wire Dossier

Raylumis

tanezumab · Pfizer Europe MA EEIG
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Raylumis, covering 2022-02-15 to 2022-02-15. Get the full timeline:

Most recent: EMA Refused: Raylumis (tanezumab) — Pfizer Europe MA EEIG

See pricing